Jan 06, 2020
Lannett Launches Venlafaxine ER Tablets And Lidocaine Topical Solution 4%
Dec 12, 2019
Lannett To Commence Marketing Generic Adderall® XR
Dec 04, 2019
Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
Nov 06, 2019
Lannett Announces Fiscal 2020 First-Quarter Financial Results
Oct 30, 2019
Lannett To Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call On Wednesday, November 6
Oct 01, 2019
Lannett Enters Into Distribution Agreement For Generic ADVAIR DISKUS®
Sep 27, 2019
Lannett Announces Closing Of $86.25 Million Of Convertible Senior Notes Due 2026
Sep 25, 2019
Lannett Announces pricing of $75 million of Convertible Senior Notes Due 2026
Sep 24, 2019
Lannett Announces Offering of $75 million of Convertible Senior Notes Due 2026
Aug 28, 2019
Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets; Launch To Commence Shortly
Aug 27, 2019
Lannett Announces Fiscal 2019 Fourth-Quarter, Full-Year Financial Results; Issues Guidance For Fiscal 2020
Aug 20, 2019
Lannett To Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Tuesday, August 27
Jul 08, 2019
Lannett Enters Into Distribution Agreement For Levothyroxine
Jul 03, 2019
FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application
Jun 18, 2019
Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules
Jun 12, 2019
Lannett To Participate At Two Investor Conferences In June
Jun 05, 2019
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®
May 29, 2019
Lannett Commences Marketing Generic Concerta®
May 24, 2019
Lannett Announces CFO Retirement
May 23, 2019
Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors